EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Allergen Immunotherapy
DOI: 10.1111/all.13317 Publication Date: 2017-09-23T07:02:45Z
ABSTRACT
Abstract Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth general population. Symptoms AR can be controlled with allergen avoidance measures pharmacotherapy. However, many patients continue to have ongoing symptoms impaired quality life; pharmacotherapy may also induce some side‐effects. Allergen immunotherapy (AIT) represents only currently available treatment that targets underlying pathophysiology, it disease‐modifying effect. Either subcutaneous (SCIT) or sublingual (SLIT) routes used. This Guideline has been prepared by European Academy Allergy Clinical Immunology's (EAACI) Taskforce on AIT for part EAACI presidential project “EAACI Guidelines Immunotherapy.” It aims provide evidence‐based clinical recommendations informed formal systematic review meta‐analysis. Its generation followed Appraisal Research Evaluation (AGREE II) approach. The process included involvement full range stakeholders. In general, broad evidence efficacy exists but product‐specific evaluation recommended. SCIT SLIT are recommended both seasonal perennial its short‐term benefit. strongest long‐term benefit documented grass (especially tablets) where seen. To achieve efficacy, minimum 3 years therapy Many gaps in base exist, particularly around use children.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (223)
CITATIONS (542)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....